AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) has been given a $4.00 price objective by equities research analysts at Maxim Group in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target indicates a potential upside of 99.00% from the stock’s previous close.
A number of other brokerages have also recently issued reports on AEZS. HC Wainwright set a $3.00 price objective on shares of AEterna Zentaris and gave the company a “buy” rating in a research note on Wednesday, November 29th. ValuEngine raised shares of AEterna Zentaris from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. AEterna Zentaris has an average rating of “Hold” and an average target price of $4.33.
AEterna Zentaris (NASDAQ AEZS) opened at $2.01 on Thursday. AEterna Zentaris has a 52 week low of $0.78 and a 52 week high of $4.25.
COPYRIGHT VIOLATION NOTICE: “Maxim Group Analysts Give AEterna Zentaris (AEZS) a $4.00 Price Target” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/12/21/maxim-group-analysts-give-aeterna-zentaris-aezs-a-4-00-price-target.html.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.